Fig. 1: LNP-mRNA treatment for pulmonary fibrosis and relevant mechanisms. | Nature Communications

Fig. 1: LNP-mRNA treatment for pulmonary fibrosis and relevant mechanisms.

From: Targeted immunotherapy rescues pulmonary fibrosis by reducing activated fibroblasts and regulating alveolar cell profile

Fig. 1

Overactivated fibroblasts induce pulmonary fibrosis and increase ECM stiffness, which hinders AT2 to AT1 differentiation resulting in PATS accumulation and fibrosis progression. Transient FAPCAR-T cells generated in vivo via LNP-mRNA can eliminate overactivated fibroblasts and promote lung regeneration via alveolar epithelial polarization. (BLM: bleomycin; LNP: lipid nanoparticle; ECM: extracellular matrix; AT1/2: alveolar epithelial type I/II; PATS: pre-alveolar type I transitional cell state). Created in BioRender65.

Back to article page